Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation

被引：1

作者：

Canichella, Martina ^{[1
]}

de Fabritiis, Paolo ^{[1
,2
]}

机构：

[1] St Eugenio Hosp, ASL Roma2, Haematol Unit, Rome, Italy

[2] Tor Vergata Univ, Dept Biomed & Prevent, I-00133 Rome, Italy

来源：

BIOMEDICINES | 2024年 / 12卷 / 08期

关键词：

acute myeloid leukemia (AML); allogeneic stem cell transplantation (ASCT); cellular therapy; donor lymphocyte infusion (DLI); chimeric antigen receptor (CAR)-T cells; next-generation CAR-T cells; universal CAR-T (UCAR-T); UniCAR technology; CHIMERIC ANTIGEN RECEPTOR; DONOR LYMPHOCYTE INFUSION; CAR-T-CELLS; INDUCED KILLER-CELLS; LEUKOCYTE INFUSIONS; RISK-FACTORS; AML PATIENTS; IMMUNOTHERAPY; THERAPY; ADULTS;

D O I：

10.3390/biomedicines12081721

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Allogeneic stem cell transplant (ASCT) remains the only treatment option for patients with high-risk acute myeloid leukemia (AML). Recurrence of leukemic cells after ASCT represents a dramatic event associated with a dismal outcome, with a 2-year survival rate of around 20%. Adoptive cell therapy (ACT) is a form of cell-based strategy that has emerged as an effective therapy to treat and prevent post-ASCT recurrence. Lymphocytes are the principal cells used in this therapy and can be derived from a hematopoietic stem cell donor, the patient themselves, or healthy donors, after being engineered to express the chimeric antigen receptor (CAR-T and UniCAR-T). In this review, we discuss recent advances in the established strategy of donor lymphocyte infusion (DLI) and the progress and challenges of CAR-T cells.

引用

页数：16

共 84 条

[51] Chimeric antigen receptor T-cell therapy - assessment and management of toxicities [J].

Neelapu, Sattva S. ;

Tummala, Sudhakar ;

Kebriaei, Partow ;

Wierda, William ;

Gutierrez, Cristina ;

Locke, Frederick L. ;

Komanduri, Krishna V. ;

Lin, Yi ;

Jain, Nitin ;

Daver, Naval ;

Westin, Jason ;

Gulbis, Alison M. ;

Loghin, Monica E. ;

de Groot, John F. ;

Adkins, Sherry ;

Davis, Suzanne E. ;

Rezvani, Katayoun ;

Hwu, Patrick ;

Shpall, Elizabeth J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (01) :47-62

[52] Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia [J].

O'Hear, Carol ;

Heiber, Joshua F. ;

Schubert, Ingo ;

Fey, Georg ;

Geiger, Terrence L. .

HAEMATOLOGICA, 2015, 100 (03) :336-344

[53] Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML [J].

Pedersen, Maya Graham ;

Moller, Bjarne Kuno ;

Bak, Rasmus O. .

BIOMEDICINES, 2022, 10 (10)

[54] Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia [J].

Pei, Kunlin ;

Xu, Haoyu ;

Wang, Pengfei ;

Gan, Wening ;

Hu, Zhengbin ;

Su, Xiaoling ;

Zhang, Hui ;

He, Yingyi .

CANCER MEDICINE, 2023, 12 (08) :9655-9661

[55] CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia [J].

Perez-Amill, Lorena ;

Armand-Ugon, Mercedes ;

Pena, Sergio ;

Casals, Maria Val ;

Santos, Claudio ;

Frigola, Gerard ;

Minguela, Alfredo ;

Torralba, Alex Bataller ;

Casanovas, Berta ;

Alamo, Jose ;

Uribe, Mireia ;

Sanchez-Martinez, Diego ;

Tirado, Nestor ;

Bueno, Clara ;

Romecin, Paola Alejandra ;

Menendez, Pablo ;

Martinez, Antonio ;

Rovira, Montserrat ;

Esteve, Jordi ;

Urbano-Ispizua, Alvaro ;

Delgado, Julio ;

Juan, Manel ;

Klein-Gonzalez, Nela .

BLOOD, 2022, 140 :7379-7381

[56] Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia [J].

Petrov, Jessica C. ;

Wada, Masayuki ;

Pinz, Kevin G. ;

Yan, Lulu E. ;

Chen, Kevin H. ;

Shuai, Xiao ;

Liu, Hua ;

Chen, Xi ;

Leung, Lai-Han ;

Salman, Huda ;

Hagag, Nabil ;

Liu, Fang ;

Jiang, Xun ;

Ma, Yupo .

LEUKEMIA, 2018, 32 (06) :1317-1326

[57] Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity [J].

Pievani, Alice ;

Borleri, Gianmaria ;

Pende, Daniela ;

Moretta, Lorenzo ;

Rambaldi, Alessandro ;

Golay, Josee ;

Introna, Martino .

BLOOD, 2011, 118 (12) :3301-3310

[58] Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies [J].

Poirot, Laurent ;

Philip, Brian ;

Schiffer-Mannioui, Cecile ;

Le Clerre, Diane ;

Chion-Sotinel, Isabelle ;

Derniame, Sophie ;

Potrel, Pierrick ;

Bas, Cecile ;

Lemaire, Laetitia ;

Galetto, Roman ;

Lebuhotel, Celine ;

Eyquem, Justin ;

Cheung, Gordon Weng-Kit ;

Duclert, Aymeric ;

Gouble, Agnes ;

Arnould, Sylvain ;

Peggs, Karl ;

Pule, Martin ;

Scharenberg, Andrew M. ;

Smith, Julianne .

CANCER RESEARCH, 2015, 75 (18) :3853-3864

[59] Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design [J].

Qin, Haiying ;

Yang, Lila ;

Chukinas, John A. ;

Shah, Nirali ;

Tarun, Samiksha ;

Pouzolles, Marie ;

Chien, Christopher D. ;

Niswander, Lisa M. ;

Welch, Anthony R. ;

Taylor, Naomi ;

Tasian, Sarah K. ;

Fry, Terry J. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)

[60] Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+Acute Myeloid Leukemia (AML) [J].

Sallman, David A. ;

DeAngelo, Daniel J. ;

Pemmaraju, Naveen ;

Dinner, Shira ;

Gill, Saar ;

Olin, Rebecca L. ;

Wang, Eunice S. ;

Konopleva, Marina ;

Stark, Eileen ;

Korngold, Ana ;

Haider, Asifa ;

Backhouse, Kate ;

Figliola, Carolyn ;

Lee, Daniel J. ;

Frattini, Mark G. ;

Brownstein, Carrie ;

Roboz, Gail J. .

BLOOD, 2022, 140 :2371-2373

← 1 2 3 4 5 6 7 8 9 →